Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;18(3):E91-E92.
doi: 10.5489/cuaj.8525.

A multidisciplinary discussion of BladderPath

Marie-Pier St-Laurent  1 , John P Sfakianos  2 , Tracy L Rose  3 , Peter Chung  4 , Wassim Kassouf  5 , Alexandre R Zlotta  6 , Brant Inman  7 , Peter C Black  1
Affiliations

A multidisciplinary discussion of BladderPath

Marie-Pier St-Laurent et al. Can Urol Assoc J. 2024 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

COMPETING INTERESTS: Dr. Rose serves as site PI for clinical trials supported by AstraZeneca, BMS, Genentech, Merck, and Syndax, with research funding to the institution (no direct payments received). Dr. Chung has received grants and/or honoraria from AbbVie, Knight, Tersera, Tolmar, and Verity. Dr. Kassouf has participated in advisory boards for AbbVie, Astellas, Bayer, BMS, EMD Serono, Ferring, Janssen, Merck, Roche, and Sesen Bio; and is the local PI on several clinical trials supported by Astra Zeneca, BMS, Janssen, Pfizer, Sesen Bio, and Theralase. Dr. Zlotta has been an advisory board member for AstraZeneca, Ferring, Janssen, MIR Scientific, Theralase, Tolmar, and Verity Pharmaceuticals. Dr. Inman has been an advisory board member for combat Medical, Janssen, Johnson & Johnson, Seattle Genetics, and Urogen; and has participated in clinical trials supported by Biom’Up, CG Oncology, combat Medical, Genentech-Roche, Taris Biomedical, and Seattle Genetics. Dr. Black has been an advisory board member for AbbVie, Astellas, AstraZeneca, Bayer, BMS, EMD Serono, Ferring, Janssen, MDxHealth, Merck, Minogue, Nonagen, Nanology, Pfizer, Protara, QED, Roche, Sanofi, Sesen, STIMIT, Therelase, UroGen, and Verity; a speakers’ bureau member for Bayer, BioSyent, Pfizer, Sanofi, and TerSera; holds a patent from Veracyte; and has participated in a clinical trials supported by Roche. The remaining authors do not report any competing personal or financial interests related to this work.

References

    1. James ND, Pirrie S, Liu W, et al. 1733MO First results from BladderPath: A randomised trial of MRI versus cystoscopic staging for newly diagnosed bladder cancer. Ann Oncol. 2022;33:S1330. doi: 10.1016/j.annonc.2022.07.1811. - DOI
    1. Bryan RT, Liu W, Pirrie SJ, et al. Comparing an imaging-guided pathway with the standard pathway for staging muscle-invasive bladder cancer: Preliminary data from the BladderPath study. Eur Urol. 2021;80:12–5. doi: 10.1016/j.eururo.2021.02.021. - DOI - PubMed
    1. Dalbagni G, Genega E, Hashibe M, et al. Cystectomy for bladder cancer: A contemporary series. J Urol. 2001;165:1111–6. doi: 10.1016/S0022-5347(05)66440-3. - DOI - PubMed
    1. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859–66. doi: 10.1056/NEJMoa022148. - DOI - PubMed
    1. Pagano F, Bassi P, Galetti TP, et al. Results of contemporary radical cystectomy for invasive bladder cancer: A clinicopathological study with an emphasis on the inadequacy of the tumor, nodes, and metastases classification. J Urol. 1991;145:45–50. doi: 10.1016/S0022-5347(17)38244-7. - DOI - PubMed

LinkOut - more resources